Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
Completed
PV-Nord
Phase 2
2004-09-01
Interferon alfa is an effective treatment of polycythemia vera (PV), but about 20% of
patients discontinue their treatment because of side effects and treatment schedule (three
times per week administration). The pegylated form of interferon alfa-2a has shown a better
tolerance in hepatitis patients and is administered only once a week. The purpose of this
study is to determine efficacy and safety of pegylated interferon alfa-2a in the treatment of
PV patients.
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Completed
Novartis Pharmaceuticals
Phase 3
2010-10-27
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of
ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera
(PV) who are resistant to or intolerant of hydroxyurea (HU).
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Completed
Incyte Corporation
Phase 3
2010-10-27
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of
ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera
(PV) who are resistant to or intolerant of hydroxyurea (HU).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
